Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Baldness reversed by chemotherapy

Efficacy of simvastatin in plaque psoriasis: A pilot study

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce Strober, MD,

Remission and time of resolution of nail psoriasis during infliximab therapy Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Dermatology physician extenders: A new risk factor?

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Treatment of psoriasis vulgaris using low-dose naltrexone

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Infectious rash after riding elephants

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Mark D. Heibel, MD, Haley D. Heibel, MS JAAD Case Reports

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis Alexander Nast, Anja Jacobs,

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Efficacy and safety of oxymetazoline cream 1

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Presentation transcript:

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) Andrew Blauvelt, MD, MBA, Melinda Gooderham, MD, MSc, Lars Iversen, MD, DMSc, Susan Ball, PhD, Lu Zhang, MS, Noah O. Agada, MD, Kristian Reich, MD Journal of the American Academy of Dermatology Volume 77, Issue 5, Pages 855-862 (November 2017) DOI: 10.1016/j.jaad.2017.06.153 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Time course of PASI response rates through 108 weeks of treatment with the recommended ixekizumab dosing regimen. PASI 75 (A), PASI 90 (B), and PASI 100 (C) response rates at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation; MI, modified multiple imputation; PASI 75/90/100, 75/90/100 percent improvement from baseline in the Psoriasis Area and Severity Index. Journal of the American Academy of Dermatology 2017 77, 855-862DOI: (10.1016/j.jaad.2017.06.153) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Time course of sPGA response rates through 108 weeks of treatment with the recommended ixekizumab dosing regimen. sPGA (0,1) (A) and sPGA (0) (B) response rates at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation; mMI, modified multiple imputation; sPGA (0,1) or (0), static Physician's Global Assessment score of 0 or 1 (0,1) or 0 (0). Journal of the American Academy of Dermatology 2017 77, 855-862DOI: (10.1016/j.jaad.2017.06.153) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Fingernail, scalp, and nonpustular palmoplantar psoriasis clearance rates at 108 weeks with recommended ixekizumab dosing regimen. A, NAPSI = 0 response rate at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. Only fingernail psoriasis was assessed in UNCOVER-3. B, PSSI = 0 and PPASI 100 response rate at 108 weeks for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. Response rates are determined for patients with baseline fingernail, scalp, or nonpustular palmoplantar psoriasis. The as-observed sample size for each measure is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation, mMI, modified nonresponder imputation; NAPSI = 0, Nail Psoriasis Severity Index score of 0; PPASI 100, 100% improvement from baseline in the Palmoplantar Psoriasis Area and Severity Index; PSSI = 0, Psoriasis Scalp Severity Index score of 0. Journal of the American Academy of Dermatology 2017 77, 855-862DOI: (10.1016/j.jaad.2017.06.153) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Long-term efficacy response rates for the recommended dosing regimen excluding patient visits with increased dose frequency. PASI 75 (A) and sPGA (0,1) (B) response rates for each visit weeks 60-108 for the ixekizumab every 2 weeks (for weeks 0-12) and then ixekizumab every 4 weeks (for weeks 13-108) dosing regimen including (+ IXE Q2W) and excluding (– IXE Q2W) data from visits with patients receiving ixekizumab every 2 weeks. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. IXE, Ixekizumab; MI, multiple imputation; mMI, modified multiple imputation; PASI 75, 75% improvement from baseline in the Psoriasis Area and Severity Index; Q2W, every 2 weeks; sPGA (0,1), static Physician's Global Assessment score of 0 or 1. Journal of the American Academy of Dermatology 2017 77, 855-862DOI: (10.1016/j.jaad.2017.06.153) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions